340 related articles for article (PubMed ID: 26181201)
1. Aggregated α-synuclein and complex I deficiency: exploration of their relationship in differentiated neurons.
Reeve AK; Ludtmann MH; Angelova PR; Simcox EM; Horrocks MH; Klenerman D; Gandhi S; Turnbull DM; Abramov AY
Cell Death Dis; 2015 Jul; 6(7):e1820. PubMed ID: 26181201
[TBL] [Abstract][Full Text] [Related]
2. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain.
Devi L; Raghavendran V; Prabhu BM; Avadhani NG; Anandatheerthavarada HK
J Biol Chem; 2008 Apr; 283(14):9089-100. PubMed ID: 18245082
[TBL] [Abstract][Full Text] [Related]
3. Neuronal complex I deficiency occurs throughout the Parkinson's disease brain, but is not associated with neurodegeneration or mitochondrial DNA damage.
Flønes IH; Fernandez-Vizarra E; Lykouri M; Brakedal B; Skeie GO; Miletic H; Lilleng PK; Alves G; Tysnes OB; Haugarvoll K; Dölle C; Zeviani M; Tzoulis C
Acta Neuropathol; 2018 Mar; 135(3):409-425. PubMed ID: 29270838
[TBL] [Abstract][Full Text] [Related]
4. Targeting α-synuclein aggregation and its role in mitochondrial dysfunction in Parkinson's disease.
Haque ME; Akther M; Azam S; Kim IS; Lin Y; Lee YH; Choi DK
Br J Pharmacol; 2022 Jan; 179(1):23-45. PubMed ID: 34528272
[TBL] [Abstract][Full Text] [Related]
5. Alpha-synuclein: Pathology, mitochondrial dysfunction and neuroinflammation in Parkinson's disease.
Rocha EM; De Miranda B; Sanders LH
Neurobiol Dis; 2018 Jan; 109(Pt B):249-257. PubMed ID: 28400134
[TBL] [Abstract][Full Text] [Related]
6. α-Synuclein and mitochondria: partners in crime?
Nakamura K
Neurotherapeutics; 2013 Jul; 10(3):391-9. PubMed ID: 23512373
[TBL] [Abstract][Full Text] [Related]
7. Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein alpha-synuclein.
Nakamura K; Nemani VM; Azarbal F; Skibinski G; Levy JM; Egami K; Munishkina L; Zhang J; Gardner B; Wakabayashi J; Sesaki H; Cheng Y; Finkbeiner S; Nussbaum RL; Masliah E; Edwards RH
J Biol Chem; 2011 Jun; 286(23):20710-26. PubMed ID: 21489994
[TBL] [Abstract][Full Text] [Related]
8. α-Synuclein and mitochondrial dysfunction in Parkinson's disease.
Mullin S; Schapira A
Mol Neurobiol; 2013 Apr; 47(2):587-97. PubMed ID: 23361255
[TBL] [Abstract][Full Text] [Related]
9. α-Synuclein aggregation and transmission in Parkinson's disease: a link to mitochondria and lysosome.
Wang R; Sun H; Ren H; Wang G
Sci China Life Sci; 2020 Dec; 63(12):1850-1859. PubMed ID: 32681494
[TBL] [Abstract][Full Text] [Related]
10. The Overcrowded Crossroads: Mitochondria, Alpha-Synuclein, and the Endo-Lysosomal System Interaction in Parkinson's Disease.
Lin KJ; Lin KL; Chen SD; Liou CW; Chuang YC; Lin HY; Lin TK
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31731450
[TBL] [Abstract][Full Text] [Related]
11. The rescue of microtubule-dependent traffic recovers mitochondrial function in Parkinson's disease.
Esteves AR; Gozes I; Cardoso SM
Biochim Biophys Acta; 2014 Jan; 1842(1):7-21. PubMed ID: 24120997
[TBL] [Abstract][Full Text] [Related]
12. p38 MAPK-DRP1 signaling is involved in mitochondrial dysfunction and cell death in mutant A53T α-synuclein model of Parkinson's disease.
Gui C; Ren Y; Chen J; Wu X; Mao K; Li H; Yu H; Zou F; Li W
Toxicol Appl Pharmacol; 2020 Feb; 388():114874. PubMed ID: 31881179
[TBL] [Abstract][Full Text] [Related]
13. Changes in Drp1 Function and Mitochondrial Morphology Are Associated with the α-Synuclein Pathology in a Transgenic Mouse Model of Parkinson's Disease.
Portz P; Lee MK
Cells; 2021 Apr; 10(4):. PubMed ID: 33924585
[TBL] [Abstract][Full Text] [Related]
14. Region specific mitochondrial impairment in mice with widespread overexpression of alpha-synuclein.
Subramaniam SR; Vergnes L; Franich NR; Reue K; Chesselet MF
Neurobiol Dis; 2014 Oct; 70():204-13. PubMed ID: 25016198
[TBL] [Abstract][Full Text] [Related]
15. Common Mechanisms Underlying α-Synuclein-Induced Mitochondrial Dysfunction in Parkinson's Disease.
Sohrabi T; Mirzaei-Behbahani B; Zadali R; Pirhaghi M; Morozova-Roche LA; Meratan AA
J Mol Biol; 2023 Jun; 435(12):167992. PubMed ID: 36736886
[TBL] [Abstract][Full Text] [Related]
16. V63 and N65 of overexpressed α-synuclein are involved in mitochondrial dysfunction.
Zhang H; Liu J; Wang X; Duan C; Wang X; Yang H
Brain Res; 2016 Jul; 1642():308-318. PubMed ID: 27048753
[TBL] [Abstract][Full Text] [Related]
17. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.
Perfeito R; Cunha-Oliveira T; Rego AC
Free Radic Biol Med; 2013 Sep; 62():186-201. PubMed ID: 23743292
[TBL] [Abstract][Full Text] [Related]
18. The novel Parkinson's disease linked mutation G51D attenuates in vitro aggregation and membrane binding of α-synuclein, and enhances its secretion and nuclear localization in cells.
Fares MB; Ait-Bouziad N; Dikiy I; Mbefo MK; Jovičić A; Kiely A; Holton JL; Lee SJ; Gitler AD; Eliezer D; Lashuel HA
Hum Mol Genet; 2014 Sep; 23(17):4491-509. PubMed ID: 24728187
[TBL] [Abstract][Full Text] [Related]
19. Alpha-synuclein mitochondrial interaction leads to irreversible translocation and complex I impairment.
Martínez JH; Fuentes F; Vanasco V; Alvarez S; Alaimo A; Cassina A; Coluccio Leskow F; Velazquez F
Arch Biochem Biophys; 2018 Aug; 651():1-12. PubMed ID: 29702063
[TBL] [Abstract][Full Text] [Related]
20. Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease.
Büeler H
Exp Neurol; 2009 Aug; 218(2):235-46. PubMed ID: 19303005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
